03/13/2026
sïParadigm Diagnostic Informatics is proud to announce its selection as a Designated Laboratory for the National Cancer Institute (NCI) Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice, known as ComboMATCH.
The NCI ComboMATCH initiative is a groundbreaking precision medicine study that aims to evaluate the effectiveness of new drug combinations for patients with advanced solid tumors based on the unique genetic makeup of their tumors.
Through this collaboration, patients who receive comprehensive solid tumor genomic testing with sïParadigm Diagnostic Informatics may be identified as potential candidates for various ComboMATCH treatment trials. These trials evaluate whether drug combinations directed by genetic testing can provide better outcomes for patients with locally advanced or advanced solid tumors.
About ComboMATCH
ComboMATCH is a precision medicine initiative sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health. A unique initiative to test new combinations of cancer drugs guided by tumor biology, ComboMATCH aims to pair patients with locally advanced or advanced solid tumors with a therapy that has the potential to manage their cancer. The study will also assist physicians in devising more effective treatment strategies. ComboMATCH is led by the ECOG-ACRIN Cancer Research Group and the NCI through the National Clinical Trials Network (NCTN). ComboMATCH treatment trials are conducted by the NCI funded NCTN research groups in the United States.
These include the Alliance for Clinical Trials in Oncology, Children’s Oncology Group, ECOG-ACRIN Cancer Research Group, NRG Oncology, and SWOG Cancer Research Network. To learn more about ComboMATCH, visit:
www.ecog-acrin.org/combomatch and
www.cancer.gov/research/infrastructure/clinical-trials/featured/combomatch
